On Thursday, BTIG changed its view on Cue Health Inc (NASDAQ:HLTH), downgrading the stock from Buy to Neutral. The diagnostics company, known for its 250,000+ instrument installed base, has been recognized for significantly reducing its costs by approximately $200 million. However, concerns have emerged about its financial runway and pending regulatory approvals.
Cue Health ended the year 2023 with $81 million in cash after a burn rate of roughly $30 million in the last quarter. BTIG estimates that the company has a cash runway of about three quarters, a precarious position in a challenging capital market environment. The firm is also awaiting multiple approvals from the Food and Drug Administration (FDA).
The FDA's indication in early January that Cue's flu/COVID Emergency Use Authorization (EUA) is not a priority has been identified as a significant setback for the company's outlook in 2024. Analysts now anticipate that it may take until summer or fall to receive further FDA approvals. With estimated operating expenses for 2024 ranging between $160 million and $200 million, and quarterly revenue projections of only $10 million to $25 million, there are concerns about the company's financial sustainability.
The path forward for Cue Health is seen as difficult, with the possibility of improvement hinging on the FDA's actions. However, the uncertainty surrounding the timing of additional FDA approvals or a potential capital raise has led to the decision to downgrade the stock. BTIG highlights the need for greater clarity on Cue Health's progress with expanding its test menu through FDA regulatory approvals before reconsidering its position.
InvestingPro Insights
As Cue Health Inc. navigates through a period of financial uncertainty and regulatory hurdles, recent data from InvestingPro provides a nuanced view of the company's current standing. Cue Health's management has been proactive in its approach to capital allocation, as evidenced by aggressive share buybacks, an InvestingPro Tip that suggests a strong belief in the company's intrinsic value. Additionally, despite the challenges, the company maintains a favorable liquidity position, holding more cash than debt on its balance sheet, which could provide some cushion in these turbulent times.
InvestingPro Data further indicates that Cue Health's market capitalization stands at a modest $44.84 million. The company's Price / Book multiple, as of the last twelve months leading up to Q3 2023, is remarkably low at 0.12, which may attract investors looking for undervalued opportunities. However, the financial metrics also reflect the company's difficulties, with a significant revenue decline of 62.41% during the same period. These figures underscore the importance of the pending FDA approvals for the company's future performance and the necessity of cost management highlighted by BTIG.
For readers looking to delve deeper into Cue Health's financial health and future prospects, there are additional InvestingPro Tips available that could provide further clarity, including insights on the company's cash burn rate and analysts' sales expectations. To access these tips and more, readers can visit InvestingPro and use the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription. Note that there are 16 more InvestingPro Tips listed, which could be instrumental in making a more informed investment decision.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.